Gene Logic Releases Improved Software for Discovering Drug Targets and Assessing Safety of Compounds
GAITHERSBURG, MD -- March 10, 2005 -- Genesis Enterprise System 2.5 Responds to Customer Needs, Offers Expanded Capabilities.
Gene Logic Inc. (NASDAQ:GLGC) has released a significant upgrade of its enterprise software system, Genesis Enterprise System(TM) 2.5. Genesis Enterprise System 2.5 further expands and accelerates researchers’ ability to assess drug risks using genomics and toxicogenomics data and related clinical information in a biologically relevant context.
Pharmaceutical and biotechnology researchers can use Genesis Enterprise System 2.5 to import and analyze their own Affymetrix GeneChip(R) array data and annotate their samples. Customers who subscribe to Gene Logic’s BioExpress(R) and ToxExpress(R) Systems employ Genesis Enterprise System 2.5 to efficiently analyze, manage, and store large amounts of array data and associated clinical, experimental, and genomic information. The latest software update reflects significant customer input regarding group-share abilities for a collaborative, secure environment and visualization tools for rapid, simultaneous examination of expression data and clinical attributes.
The Genesis Enterprise System 2.5 includes improved tools for:
-- Correlating gene expression with clinical attributes. Genesis Enterprise System 2.5 can be used to identify gene expression changes in individual genes when a therapeutic is administered.
-- Identifying genes associated with disease. Genesis Enterprise System 2.5 can be used to identify genes that distinguish diseased tissues from normal samples.
-- Prioritizing pathway and target analysis. Genesis Enterprise System 2.5 can be used to prioritize potential drug targets and disease pathways by comparing gene expression differences between normal and diseased tissue samples.
-- Integrating classical analysis tools with powerful new algorithms and visualization tools. Genesis Enterprise System 2.5 allows rapid quantification of sample information and analysis of related gene expression regulation in comparison to public reference data, clinical diagnostics, pathology findings and laboratory processing metrics.
Dennis A. Rossi, senior vice president and general manager for genomics at Gene Logic, commented, “Our customers seek to understand expression data as they relate to donor information and conventional pathology parameters. Genesis 2.5 expands the power of the underlying expression data by efficiently enabling researchers to develop statistical correlations and reveal biological relationships between complex expression and detailed clinical data. Users of Genesis 2.5 have the opportunity to potentially identify surrogate biomarkers and increase their insight into mechanism of action and disease progression.”
Additional information about Genesis Enterprise System 2.5 is available at www.genelogic.com.
Gene Logic Overview
Gene Logic aspires to be the most valued drug development services provider for the pharmaceutical industry. Gene Logic applies its broad and unique mix of technologies, talent and methodologies to work on behalf of its partners to enable pharmaceutical and biotechnology companies to make more informed, more reliable and more predictive decisions at each point in the highly complex and costly drug development process. For more information, visit www.genelogic.com or call toll-free - 1/800/GENELOGIC.
- Contact Information
- Robert G. Burrows
- Investor contact
- Gene Logic Inc.
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.